Lisata Therapeutics, Inc. (LSTA) P/E Ratio History
Historical price-to-earnings valuation from 2017 to 2018
Loading P/E history...
LSTA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Lisata Therapeutics, Inc. (LSTA) trades at a price-to-earnings ratio of -1.7x, with a stock price of $3.23 and trailing twelve-month earnings per share of $-1.91.
The current P/E is 176% below its 5-year average of 2.2x. Over the past five years, LSTA's P/E has ranged from a low of 1.4x to a high of 3.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, LSTA trades at a 108% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, LSTA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LSTA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LSTA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $243M | 4.9Lowest | 4.84Best | +49%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LSTA Historical P/E Data (2017–2018)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $87.60 | $46.83 | 1.9x | -16% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $52.65 | $37.91 | 1.4x | -38% |
| FY2017 Q3 | Sat Sep 30 2017 00:00:00 GM | $53.70 | $29.05 | 1.8x | -17% |
| FY2017 Q2 | Fri Jun 30 2017 00:00:00 GM | $69.75 | $18.38 | 3.8x | +71% |
Average P/E for displayed period: 2.2x
See LSTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LSTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LSTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLSTA — Frequently Asked Questions
Quick answers to the most common questions about buying LSTA stock.
Is LSTA stock overvalued or undervalued?
LSTA trades at -1.7x P/E, below its 5-year average of 2.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does LSTA's valuation compare to peers?
Lisata Therapeutics, Inc. P/E of -1.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is LSTA's PEG ratio?
LSTA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2017-2018.